Annual Meeting 2015: New Ibrutinib Combination Regimen Shows Substantial Benefits in Relapsed Chronic Lymphocytic Leukemia - 101271

Spotlight
Video

Annual Meeting 2015: New Ibrutinib Combination Regimen Shows Substantial Benefits in Relapsed Chronic Lymphocytic Leukemia

EMJ has 458 videos Subscribe Here

Loading........
Description: An interim analysis of a large phase III study suggests that the combination of ibrutinib and bendamustine/rituximab (BR) improves outcomes for patients with chronic-lymphocytic leukemia (CLL) that worsened despite prior therapy.

At a median follow-up of 17 months, patients who received ibrutinib and BR had an 80% lower risk of disease progression or death than those who received placebo and BR. Based on this striking benefit, patients were permitted to cross over from the placebo group to receive ibrutinib.

Presented by Asher Alban Akmal Chanan-Khan, MD, Mayo Clinic, Jacksonville, FL, at ASCO 2015

–––

European Medical Journal

Website: http://emjreviews.com/...
Twitter: https://twitter.com/EMJRevi...
Facebook: https://www.facebook.com/em...
Shared By : EMJ
Posted on : 06/03/15
Added : 3 years ago



Recommended

Nothing found.

More From EMJ

Nothing found.